140 related articles for article (PubMed ID: 7479389)
41. An estrogen receptor basis for raloxifene action in bone.
Bryant HU; Glasebrook AL; Yang NN; Sato M
J Steroid Biochem Mol Biol; 1999; 69(1-6):37-44. PubMed ID: 10418979
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor.
Zeng Y; Yokohira M; Saoo K; Takeuchi H; Chen Y; Yamakawa K; Matsuda Y; Kakehi Y; Imaida K
Carcinogenesis; 2005 Jun; 26(6):1109-16. PubMed ID: 15731164
[TBL] [Abstract][Full Text] [Related]
43. Phase II evaluation of Ly156758 in metastatic breast cancer.
Buzdar AU; Marcus C; Holmes F; Hug V; Hortobagyi G
Oncology; 1988; 45(5):344-5. PubMed ID: 3412740
[TBL] [Abstract][Full Text] [Related]
44. Use of an extracellular matrix material as a vaccine carrier and adjuvant.
Suckow MA; Hall P; Wolter W; Sailes V; Hiles MC
Anticancer Res; 2008; 28(5A):2529-34. PubMed ID: 19035274
[TBL] [Abstract][Full Text] [Related]
45. Effect of the nonsteroidal antiestrogen ZK 119.010 on growth and metastasis of the EnDA endometrial carcinoma.
Horn DW; Vollmer G; von Angerer E; Schneider MR
Int J Cancer; 1994 Aug; 58(3):426-9. PubMed ID: 8050824
[TBL] [Abstract][Full Text] [Related]
46. Antagonism of estrogen action with a new benzothiophene derived antiestrogen.
Black LJ; Jones CD; Falcone JF
Life Sci; 1983 Feb; 32(9):1031-6. PubMed ID: 6827921
[TBL] [Abstract][Full Text] [Related]
47. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells.
Simard J; Sanchez R; Poirier D; Gauthier S; Singh SM; Merand Y; Belanger A; Labrie C; Labrie F
Cancer Res; 1997 Aug; 57(16):3494-7. PubMed ID: 9270018
[TBL] [Abstract][Full Text] [Related]
48. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats.
Sato M; Rippy MK; Bryant HU
FASEB J; 1996 Jun; 10(8):905-12. PubMed ID: 8666168
[TBL] [Abstract][Full Text] [Related]
49. Time-related effects of a triphenylethylene antiestrogen on estrogen-induced changes in uterine weight, estrogen receptors, and endometrial sensitivity in rats.
Trivedi RN; Chauhan SC; Dwivedi A; Kamboj VP; Singh MM
Contraception; 1995 Jun; 51(6):367-79. PubMed ID: 7554978
[TBL] [Abstract][Full Text] [Related]
50. Clinical effects of raloxifene hydrochloride in women.
Khovidhunkit W; Shoback DM
Ann Intern Med; 1999 Mar; 130(5):431-9. PubMed ID: 10068418
[TBL] [Abstract][Full Text] [Related]
51. The selective estrogen receptor modulator, raloxifene: reproductive assessments in adult male rats.
Hoyt JA; Fisher LF; Swisher DK; Byrd RA; Francis PC
Reprod Toxicol; 1998; 12(3):223-32. PubMed ID: 9628547
[TBL] [Abstract][Full Text] [Related]
52. Melengestrol acetate and megestrol acetate are prostatic tumor inhibiting agents.
Padilla GM; Yacullo RC; Padilla JJ; Payne B; Petrow V
Biochem Cell Biol; 1990 Oct; 68(10):1181-8. PubMed ID: 2268413
[TBL] [Abstract][Full Text] [Related]
53. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.
Jones CD; Jevnikar MG; Pike AJ; Peters MK; Black LJ; Thompson AR; Falcone JF; Clemens JA
J Med Chem; 1984 Aug; 27(8):1057-66. PubMed ID: 6431104
[TBL] [Abstract][Full Text] [Related]
54. Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens.
Wakeling AE; Valcaccia B
J Endocrinol; 1983 Dec; 99(3):455-64. PubMed ID: 6644236
[TBL] [Abstract][Full Text] [Related]
55. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Schally AV; Redding TW
Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
[TBL] [Abstract][Full Text] [Related]
56. Antiestrogens do not counteract the inhibitory effect of estradiol-17 beta on the growth of the Dunning R3327 prostatic adenocarcinoma.
Landström M; Damber JE; Bergh A; Tomic R; Carlsson-Bostedt L; Stigbrand T
Prostate; 1988; 12(4):287-98. PubMed ID: 3393491
[TBL] [Abstract][Full Text] [Related]
57. Differential effects of genistein, estradiol and raloxifene on rat osteoclasts in vitro.
Sliwiński L; Folwarczna J; Janiec W; Grynkiewicz G; Kuzyk K
Pharmacol Rep; 2005; 57(3):352-9. PubMed ID: 15985718
[TBL] [Abstract][Full Text] [Related]
58. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.
Poulin R; Merand Y; Poirier D; Levesque C; Dufour JM; Labrie F
Breast Cancer Res Treat; 1989 Oct; 14(1):65-76. PubMed ID: 2605344
[TBL] [Abstract][Full Text] [Related]
59. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
Black LJ; Sato M; Rowley ER; Magee DE; Bekele A; Williams DC; Cullinan GJ; Bendele R; Kauffman RF; Bensch WR
J Clin Invest; 1994 Jan; 93(1):63-9. PubMed ID: 8282823
[TBL] [Abstract][Full Text] [Related]
60. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
Osborne CK; Hobbs K; Clark GM
Cancer Res; 1985 Feb; 45(2):584-90. PubMed ID: 3967234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
